REG - Tristel PLC - Analyst and Investor presentation

TristelAnnouncement

05/06/2023 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230605:nRSE6547Ba&default-theme=true

RNS Number : 6547B  Tristel PLC  05 June 2023

Tristel plc

("Tristel" or the "Company")

 

Analyst and Investor presentation

 

Re. news of FDA De Novo approval for Tristel ULT as a high level disinfectant

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces that the Company will hold a presentation for analysts and investors
following this morning's announcement that Tristel ULT was approved by the FDA
as a high level disinfectant for use on endocavity ultrasound probes and skin
surface transducers.

 

Paul Swinney, CEO, and Liz Dixon, CFO, will provide details of the Company's
North America Commercial Strategy in a presentation which is open to all
existing and potential shareholders, as well as analysts.

 

The live presentation will take place on the Investor Meet Company platform at
4.30pm today, Monday 5 June 2023, and a replay facility will also be available
shortly afterwards. Questions can be submitted at any time during the live
presentation.

 

Investors can sign up to Investor Meet Company for free and add to
meet Tristel plc to register for the presentation via:
https://www.investormeetcompany.com/tristel-plc/register-investor
(https://www.investormeetcompany.com/tristel-plc/register-investor)

 

For further information please contact:

 

 Tristel plc                            Tel: 01638 721 500
 Paul Swinney, Chief Executive Officer
 Liz Dixon, Chief Financial Officer

 Walbrook PR Ltd                        Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus                           Mob: 07980 541 893
 Lianne Applegarth                      Mob: 07584 391 303

 finnCap                                Tel: 020 7220 0500
 Geoff Nash/ Charles Beeson (Corporate Finance)
 Alice Lane (ECM)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFETRTIEIIV